Zeltia: Supported By Solid Financials To Reduce Net Debt
Edison | Mar 18, 2015 08:13AM ET
Repositioning for growth
Zeltia (MADRID:ZEL) is laying the groundwork for an important 12-18 month period that could provide significant growth and value creation. Plans to restructure the group (through a reverse merger whereby its PharmaMar division will absorb the parent company, Zeltia and seek an IPO in the US could be transformational in terms of strengthening its financial and commercial abilities. Then there is the potential for the oncology pipeline to provide upside as it enters a catalyst-rich period. We raise our valuation to €1.03bn or €4.65 per share, ahead of a number of key catalysts in 2015.
Getting the right corporate structure in place
The real long-term value driver in Zeltia’s biopharma/chemicals subsidiaries is PharmaMar, with marketed (Yondelis) and late-stage (PM01183/Aplidin) oncology drugs. The group is now proposing a reverse merger whereby Zeltia will be absorbed by PharmaMar, with one PharmaMar share exchanged for one Zeltia share and PharmaMar shares then listed. We view this as a positive development in resetting the story onto the established and emerging oncology portfolio, which should then help attract significant investor interest in a potential US IPO.
While entering a catalyst-rich period
Yondelis, already marketed in 80 countries, could gain important new regulatory approvals in 2015 as a second-line treatment for STS (soft tissue sarcoma) in the US (PDUFA in July) and Japan (Q315). This could significantly boost revenues through milestones and royalties from its partners (Janssen in the US, Taiho in Japan). PM01183 (a Yondelis follow-on) has generated highly encouraging clinical data in ovarian cancer and SCLC and is poised for rapid development in 2015. Data from a Phase III study with Aplidin in multiple myeloma are due in Q415.
Supported by solid financials to reduce net debt
FY14 net revenues increased 6% to €149.7m, with EBITDA growth of 8% to €25.7m, despite a significant increase oncology R&D expense (+24% to €45.3m). With the prospect of new market launches and milestones for Yondelis, we forecast further EBITDA improvement in FY15e to €29.1m (despite higher R&D). Increased cash flow should help to further reduce net debt (FY14: €56m; FY15e: €45.7m).
Get The News You Want
Valuation: Increased to €1.03bn or €4.65 per share
We have increased our DCF model to €1.03bn (vs €930m) or €4.65/share (vs €4.19/share). This is due to a number of factors, including an increase in probability for PM01183 in SCLC (to 50% from 15%) and a positive FX benefit (US$1.10:€ vs 1.27). We note our valuation represents fair value ahead of key catalysts in 2015.
To Read the Entire Report Please Click on the pdf File Below
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.